1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.

Slides:



Advertisements
Similar presentations
Quality of health care Ilembula Lutheran Hospital Arto Vehviläinen MD, PhD.
Advertisements

COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Anchoring and Gender Effects on the Assessment of Likelihood of Success André Heiber Undergraduate Student Fort Lewis College.
A RECIPE FOR INCOHERENCE: AVERAGING TIME-TRADEOFF OR STANDARD-GAMBLE UTILITIES ACROSS HEALTH ATTRIBUTES Gordon B. Hazen, IEMS Department, Northwestern.
Dementia Patients Caregivers Quality of Life International Journal of Geriatric Psychiatry Karine Demeule.
Estimating utilities from individual preference data Some introductory remarks by Tony O’Hagan.
1 Randomization as a Concept to Improve Follow-Up and Reduce Cost in Long-Term Health Related Quality of Life Studies Addressing Cardiac Surgery Scott.
Health Economics and Technology Assessment Research Centre Katalin Érsek 1, Krisztián Kárpáti 1, Tibor Kovács 2, László Gulácsi.
Quality of life Assessment introduction
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Statistics Testing the Difference Between Proportions Statistics Mrs. Spitz Spring 2009.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
This Outcome report is based on data from patients who completed a Pain Management Programme at the RealHealth Treatment Centre in Coventry between November.
HEALTH STATUS OF ELDERLY IN SAGE COUNTRIES : ISSUES 12 TH Global Conference on Ageing Hyderabad June 11-13, 2014 Dr Somayajulu V ULIMIRI CEO and Executive.
Overview of the EQ-5D Purpose and origins of the descriptive system.
ADOLESCENT AND PARENTAL UTILITIES FOR THE HEALTH STATES ASSOCIATED WITH PELVIC INFLAMMATORY DISEASE (PID) Maria Trent, MD, MPH, Harold Lehmann, MD, PhD,
Parents’ Overall Quality of Life is Negatively Affected by Having a Child with Feeding Problems Amy J. Majewski 1, Alisha M. Neu 1, Gustavo R. Medrano.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Health-Related Quality of Life in Chronic Hepatitis B Patients Xiaoyan Guo.
Rescuing Clinical Trial Data For Economic Evaluation
1 Patient Outcomes & Experience Measurement in Podiatry Results from two NHS departments.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
New and ongoing areas of research In the EuroQol Group.
HTA – Cost Containment or Quality Instrument? Bengt Jönsson Stockholm School of Economic.
Quality of Life in People with and at Risk for Type 2 Diabetes: Findings from the Study to Help Improve Early Evaluation and Management of Risk Factors.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
1 Patient values or values from the general public.
Estimating Outcomes in Decision Analysis Brian Harris MPP Candidate Goldman School of Public Policy University of California, Berkeley.
The Effect of Cognitive Fatigue on Language in Multiple Sclerosis Leena Maria Heikkola, Päivi Hämäläinen and Juhani Ruutiainen Åbo Akademi University,
Lecture 6: Reliability and validity of scales (cont) 1. In relation to scales, define the following terms: - Content validity - Criterion validity (concurrent.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Presented By: Mohammed Al-Issa. Objectives of the Study To assess the degree of satisfaction among dialysis patients in their dialytic therapy. To assess.
Overview of Health-Related Quality of Life Measures May 22, 2014 (1:00 – 2:00 PDT) Kaiser Methods Webinar Series 1 Ron D.Hays, Ph.D.
The Overall Effect of Childhood Feeding Problems on Caregiver’s Quality of Life Amy J. Majewski 1, W. Hobart Davies 1, & Alan H. Silverman 2 University.
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Applying Expectancy-value Model to understand Health Preference An Exploratory Study Xu-Hao Zhang Department of Pharmacy National University of Singapore.
Measuring Family HRQOL Spillover Effects Using QALYs Lisa A. Prosser, PhD University of Michigan CANS Special Topics Conference October 14, 2015.
Introduction to decision analysis Jouni Tuomisto THL.
Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO Floor van Nooten, Xander Koolman, Werner Brouwer 1 A paper introduced.
Whose Life is it Anyway? Proxy v. Self reported quality of life in Childhood Cancer Survivors Penney Upton.
Conducted in the summer of 2012 at 19 COCA-I camps, with a total participation of 2725 campers.
The Quality of Life Index A Literature Survey of the Usage and Results from the Ferrans and Powers QLI.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
PACE (Psoriatic Arthritis Costs Evaluation Study) (Psoriatic Arthritis Costs Evaluation Study)
Chapter 11: Test for Comparing Group Means: Part I.
1 VAS, SG, TTO and PTO An Interactive Introduction.
Preference Assessment 1 Measuring Utilities Directly
Testing the Difference Between Proportions
M. Dakoutrou, V. Gerovasili, G. Sidiras, I. Patsaki, A. Kouvarakos, S
• the prevalence of pain related fear in patients with chronic
Types of T-tests Independent T-tests Paired or correlated t-tests
The valuation of disease-specific questionnaires for QALY analysis
Socio-Demographic Data by Age, Gender and Ethnicity
Happiness Index Analysis
Measuring outcomes Emma Frew October 2012.
International Academic Multidisciplinary Research Conference in Rome
Presentation transcript:

1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen Medical Centre

Research  Methods  Visual Analogue scale (VAS)  Subjects  Patient with dementia and their caregivers  Research problem  Do patient and their caregivers use the VAS like ‘nomal’ patients?  Scale calibration  Research question  Is the scale recalibration in dementia patients and their proxies like ‘normal’ patients  Repeating results Uble, 2005 Death Healthy

Scale calibration Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Worse imaginable health state Best imaginable health state for someone 25 years of age X X X

B > A > C Uble 2005 Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Worse imaginable health state Best imaginable health state for someone 25 years of age X X X ABC

Sample PatientsProxies Age; mean (SD)78.4 (5.8)64.5 (13.0) Gender; % female Activities of daily living; % reporting limitations N Scoring “ some ” or “ severe ” problems on the domains of mobility or self care on the EQ-5D

Results  Hypothesis Uble 2005  B > A > C  Patients  B = A > C  Patient by proxy  A > B > C  Proxy self  A > B > C

Scale calibration Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Worse imaginable health state Best imaginable health state for someone 25 years of age X X X

Conclusions  Patients follow hypothesis Uble 2005  Proxy “violate” hypothesis  proxy themselves hypothesis  Support the use of patient values  in this group…

Discussion  Why these 3 VAS’s?  Explanations  Are there more explanations than given in the discussion?  Scale proportions  Do the 3 VAS have different scales proportion Are the units the same?  Are you really discussing “scale calibrations”

Why three VAS’s  Are the ‘other two’ VAS’s in use?  If not…  Is it because we think they are not ok?  Do they include everything we want to know? 10

Explanation given Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Worse imaginable health state Best imaginable health state for someone 25 years of age X X X “As the proxy assessment of patient HRQoL is lower when compared to people of the patient’s age, it seems likely that proxies use an anchor of a person of the patient’s age with a (similar) condition instead of an anchor of a healthy person of the patient’s age.” X

Does the caregiver includes also other values or coping? 12

Coping Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Worse imaginable health state Best imaginable health state for someone 25 years of age X X X The best imaginable for such patient The best imaginable for such person Decreasing possibility of coping (possibilities to shift anchors) X

Happy fool Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Worse imaginable health state Best imaginable health state for someone 25 years of age X X X He thinks that he is ok… But that is not the case… Decreasing awarness of cognitive effects X

Judgment own efforts Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Worse imaginable health state Best imaginable health state for someone 25 years of age X X X The best imaginable what I can give this patient The best imaginable for such person Decreasing coping on judgment of own efforts X

Scale calibration Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age

Scale calibration Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Represents less utility

Disease specific utilities are a subscale of a generic scale  Rescaling necessary No disease specific problems All disease specific complains Death Healthy

Raw disease specific trade-off ten to overestimated gains  Value of life years “traded off” in TTO differently  Healthy subject:1 life year is 1.0 QALY  Sick subject:1 life year is 0.8 QALY  Life years of healthy persons are more worth than those of sick  Disutility is proportional  20% trade off at 1.00: disutility = 0.20  20% trade off at 0.80: disutility = 0.16  20% trade off at 0.60: disutility = 0.12

Scale calibration Worse imaginable health state Best imaginable health state Worse imaginable health state Best imaginable health state for someone your age Represents less utility

Solution: multiplicative model  Multiply disease specific value with average generic value of the patient group  For instance in IPSS  male age 55-64: overall QoL utility: 0.81  Most severe BPH: 0.87  Male age with most severe BPH: 0.81 x 0.87 =.7047  Maximum gain reduces from  Raw score = 0.13  Adjust score = 0.11  15 % reduction

Linear or multiplicative? 22 CaseAgeDisutility due to age 1 Disutility due to diseaseVAS AVAS BVAS C , – (25 x.90)

Conclusion  Nice paper  Surprising results given the hypotheses  But  Are all explanation in the paper?  Are indeed the scales the same? Are the additive functions possible? 23